Kidney transplant recipients are at high risk for hyperuricemia due to multiple contributing factors.
Hyperuricemia is frequently observed among patient with chronic kidney disease.
Tigulixostat vs placebo was found to be safe and effective in lowering serum urate levels among patients with gout and hyperuricemia.
Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials.
Findings from a systematic review and meta-analysis showed the relationship between gout and venous thromboembolism.
A higher serum uric acid to HDL ratio may indicate a greater preclinical inflammatory burden, according to investigators.
Investigators examined the association between uric acid levels and all-cause and cardiovascular mortality in patients with diabetes in a national population-based sample and 13 cohort studies.
The ABCG2 transporter drives urate excretion in the kidney and intestine.
Investigators explored the causality between the liability of gout on hypertension and the liability of hypertension on gout.
Early identification of patients at high risk of hyperuricemia using the triglyceride-glucose index may permit prompt intervention.